Scholarlink

<p>Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics for the treatment of multidrug-resistant (MDR) pathogens; however, their clinical translation is limited by proteolytic degradation. We developed dPA-13, an all-D-enantiomer of the 13-mer AMP PA-13, to improve resistance. dPA-13 exhibited potent bactericidal activity against <i>Pseudomonas aeruginosa</i>, superior protease stability, and a favorable safety profile. Confocal imaging and comparative proteomics revealed distinct mechanistic differences: while PA-13 localized to the membrane, dPA-13 exhibited enhanced cytoplasmic translocation. Proteomic analysis showed dPA-13 triggers a comprehensive cellular response, upregulating oxidoreductases (e.g., catalase), DNA repair machinery, and metal-ion binding proteins, while downregulating metabolic enzymes, transport permeases, and virulence factors (PilT and flagellar systems). Molecular docking corroborated these shifts, identifying high binding affinities toward critical targets, notably PilT, stabilized by specific electrostatic and hydrogen-bonding motifs at Glu394 and His397. Furthermore, <i>P. aeruginosa</i> developed resistance to dPA-13 significantly slower than to ciprofloxacin. Collectively, dPA-13 is a proteolytically robust, dual-action antimicrobial that disrupts both membrane integrity and intracellular homeostasis, positioning it as a promising candidate for recalcitrant MDR infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhanced proteolytic stability and distinct mechanisms of a D-amino acid-modified antimicrobial peptide against Pseudomonas aeruginosa

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Sirinthip Khlaychinda,
  • Utid Suriya,
  • Sittiruk Roytrakul,
  • Ratchaneewan Aunpad

摘要

Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics for the treatment of multidrug-resistant (MDR) pathogens; however, their clinical translation is limited by proteolytic degradation. We developed dPA-13, an all-D-enantiomer of the 13-mer AMP PA-13, to improve resistance. dPA-13 exhibited potent bactericidal activity against Pseudomonas aeruginosa, superior protease stability, and a favorable safety profile. Confocal imaging and comparative proteomics revealed distinct mechanistic differences: while PA-13 localized to the membrane, dPA-13 exhibited enhanced cytoplasmic translocation. Proteomic analysis showed dPA-13 triggers a comprehensive cellular response, upregulating oxidoreductases (e.g., catalase), DNA repair machinery, and metal-ion binding proteins, while downregulating metabolic enzymes, transport permeases, and virulence factors (PilT and flagellar systems). Molecular docking corroborated these shifts, identifying high binding affinities toward critical targets, notably PilT, stabilized by specific electrostatic and hydrogen-bonding motifs at Glu394 and His397. Furthermore, P. aeruginosa developed resistance to dPA-13 significantly slower than to ciprofloxacin. Collectively, dPA-13 is a proteolytically robust, dual-action antimicrobial that disrupts both membrane integrity and intracellular homeostasis, positioning it as a promising candidate for recalcitrant MDR infections.